Bod Science
Bod Science is an Australian medicinal cannabis company that develops and supplies TGA-compliant pharmaceutical-grade CBD products (Bod MediCabilis) and a clinical-stage pipeline of cannabinoid formulations, serving prescribing doctors, pharmacies, and patients with chronic conditions across Australia and the UK.
- Company typePrivate
- Founded2016
- HeadquartersSydney, Australia
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bod Science does
Bod Science Pty Ltd is an Australian privately-held medicinal cannabis company headquartered in Sydney, New South Wales, founded in 2016. The company develops and supplies TGA-compliant pharmaceutical-grade cannabis-derived medicines, with its core commercial product being Bod MediCabilis, a 5% CBD full-spectrum oil (containing LINNEA 315CSE) supplied as a prescription-only medicine through the Therapeutic Goods Administration Special Access Scheme and Authorised Prescriber pathways. Bod operates a clinical R&D pipeline spanning novel CBD, CBG, and CBN formulations (Bod Bio Absorb, Bod ECS315, ECS317, ECS100, and Bod Es310) evaluated across insomnia, Motor Neuron Disease, Long Covid, anxiety, inflammation, and animal health indications, with multiple Phase I and Phase II trials in progress at institutions including University of Sydney, University of Technology Sydney, University of South Australia, the Woolcock Institute, and Gold Coast University Hospital. A peer-reviewed Phase I pharmacokinetic study of MediCabilis was published in the British Journal of Clinical Pharmacology, and Bod holds one of only six globally validated Novel Food Applications enabling CBD sales in the UK and EU.
Bod generates revenue through prescription product sales fulfilled via a pharmacy channel and through clinical trial and observational study services (including the BODOLOS observational study). Distribution occurs through a pharmacy fulfillment network and an integrated clinic channel featuring named cannabis-medicine specialists with TeleHealth services (Ananda Clinics, Australian Access Clinics, Cannabis Doctors Australia, Tetra Health), with exclusive global distribution handled by H&H Global. The company targets the Australian market as primary and the United Kingdom as a secondary market, participating in Project Twenty21, the UK's largest medical cannabis patient study. Bod also develops proprietary delivery technologies including a wafer format and a novel protein delivery system (Project Skin) for topical anti-aging applications, indicating diversification beyond oil-based CBD into adjacent delivery and consumer formats.
Bod Science firmographics
Firmographics- Name
- Bod Science
- Legal name
- Bod Science Pty Ltd
- Website
- https://bodscience.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Bod Science is an Australian medicinal cannabis company that develops and supplies TGA-compliant pharmaceutical-grade CBD products (Bod MediCabilis) and a clinical-stage pipeline of cannabinoid formulations, serving prescribing doctors, pharmacies, and patients with chronic conditions across Australia and the UK.
- Ownership category
- akta.pro rank
Bod Science industry classification
Industry- Product category
- Medicinal Cannabis Pharmaceuticals
- NAICS
- Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- CBD/Hemp Wellness & Supplements Retail (CRANAHAC)
- akta.pro secondary industry
- Medical Cannabis Dispensaries (CRANAFAB)
Keywords
Where Bod Science is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Bod Science business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Others
Revenue model
- Prescription Medicinal Cannabis Products: Bod Science generates revenue through the sale of prescription-only medicinal cannabis products, primarily Bod MediCabilis. Pharmacies order directly from Bod once prescriptions and TGA approvals are received.
- Clinical Trial Services: Revenue from conducting clinical trials and observational studies (BODOLOS study) that generate real-world evidence on doctor prescribing habits and product efficacy, supporting regulatory registrations and commercial opportunities.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Bod Science product offering
Product offeringCore offering
Bod Science supplies pharmaceutical-grade medicinal cannabis products — primarily Bod MediCabilis (5% CBD full-spectrum oil using LINNEA 315CSE™) — as prescription-only medicines through Australia's TGA Special Access Scheme (SAS) and Authorised Prescriber pathways. The company maintains a clinical R&D pipeline of CBD, CBG, and CBN formulations (Bod Bio Absorb, Bod ECS315, Bod ECS317, Bod ECS100, Bod Es310) targeting insomnia, Motor Neuron Disease, Long Covid, anxiety, and inflammation, alongside proprietary wafer-based cannabinoid delivery technology.
Product overview
Bod Science is an Australian medicinal cannabis company providing a portfolio of pharmaceutical-grade cannabis-derived products through regulated healthcare pathways. The core product is Bod MediCabilis (5% CBD full-spectrum oil), which is supplied as a prescription-only medicine. The company maintains an active clinical trial pipeline including Bod Bio Absorb (novel CBD), Bod ECS315 (CBD extract), Bod ECS100, Bod ECS317 (CBG), and Bod Es310 (CBN) for conditions such as insomnia, anxiety, inflammation, Motor Neuron Disease, and Long Covid. Bod also develops proprietary delivery technologies including wafer-based formats, and conducts research into novel proteins for topical skincare applications. Products are distributed through pharmacies, medical clinics, and telehealth services across Australia via TGA pathways.
Differentiator
Problem solved
Functional benefit
Brands
- Bod MediCabilis: Prescription-only medicinal cannabis product offered by Bod Science.
- Bod Bio Absorb
- Bod ECS317
- Bod ECS100
- Bod ECS315
- Bod ECS310
Products and services
- Bod MediCabilis Pharmaceutical-grade 5% CBD full-spectrum oil product (MediCabilis 5% CBD with LINNEA 315CSE) supplied as a prescription-only medicine through the TGA Special Access Scheme and Authorised Prescriber pathways. For Australian doctors prescribing to eligible patients and pharmacies dispensing prescriptions.
- Bod Bio Absorb (clinical trial compound) Novel CBD compound in Bod's R&D pipeline being evaluated in a Phase II insomnia study for safety, tolerability, pharmacokinetics, and efficacy, with the goal of supporting future TGA registration for over-the-counter pharmacy sales.
- Bod ECS315 (clinical trial compound) CBD extract evaluated across multiple clinical programmes including the Emerald Study (Phase II) for Motor Neuron Disease, Long Covid symptom studies, a Phase I pharmacokinetic trial, toxicology work, and the BODOLOS observational study of real-world prescribing habits.
- Bod Es310 — CBN Insomnia Study compound CBN (cannabinol) formulation being evaluated in a Phase I CBN Insomnia Study for the treatment of primary insomnia, conducted in collaboration with the University of Sydney and The Woolcock Institute of Medical Research.
- Bod ECS317 and Bod ECS100 — Project Chang'e combination products Cannabinoid formulations — Bod ECS317 (CBG) combined with Bod ECS100 and probiotics — evaluated under Project Chang'e for stress, anxiety, and inflammation in animals, with research output intended to support future human CBG and CBD product launches.
- Project Skin — novel protein delivery for anti-aging Novel protein-based topical delivery technology being evaluated for anti-aging efficacy through inhibition of free radical damage on skin.
- Innovation Wafer Delivery Technology Proprietary wafer-based delivery format for cannabis-based medicines; Phase 1 clinical study at Nucleus Network assessed safety, tolerability and pharmacokinetics and was published in the British Journal of Clinical Pharmacology.
- CAN-REST insomnia clinical study participation Patient recruitment programme for a clinical study using cannabinoid-based medications to evaluate a novel approach to insomnia relief. Aimed at Australian patients seeking non-standard treatment for primary insomnia.
Quantifiable outcome
- 50% increase in patients' self-reported health and ability to lead a normal life (Project Twenty21 findings for CBD in inflammation)
- +3 more outcomes
Companies that use Bod Science
Customer profileSegments3 records
Ideal customer profiles3 records
Bod Science technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Bod Science partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- H&H GlobalcoreExclusive partnership agreement providing Bod with a leading distribution partner that has an established reputation, global brands and international market presence. This is a flagship partnership supporting Bod's global distribution strategy.
- Lambert Initiative (University of Sydney)coreCollaboration with the renowned Lambert Initiative for Cannabinoid Research at University of Sydney for ongoing development and definition of the future of medicinal cannabis.
- University of Technology SydneycoreCollaboration with University of Technology Sydney for research and development of medicinal cannabis products and applications.
- University of South AustraliacorePartnership with University of South Australia for ongoing research of Bod full-spectrum product (50mg CBD/mL), providing valuable information for clinical practice and future research.
- Gold Coast University HospitalminorCollaboration for Emerald Study (Phase II) evaluating the use of CBD (Bod ECS315) in slowing progression of Motor Neuron Disease.
- University of Sydney and The Woolcock Institute of Medical ResearchminorCollaboration for Phase I CBN Insomnia Study evaluating CBN (Bod Es310) for treating primary insomnia.
- Nucleus NetworkminorPhase 1 clinical study assessing safety, tolerability and pharmacokinetics of MediCabilis conducted at Nucleus Network and published in British Journal of Clinical Pharmacology.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Bod Science competitors and assessment
Company assessmentDirect peers
- Althea Group Holdings: Australian medicinal cannabis company supplying TGA-compliant pharmaceutical-grade cannabis products to Australian patients via prescription pathways. Highly comparable to Bod Science in product portfolio, regulatory approach, and pharmacy distribution model.
- Zelira Therapeutics: Australian-listed medicinal cannabis company focused on clinically validated cannabinoid formulations for insomnia, chronic pain, and other indications. Highly comparable clinical-trial-driven approach and prescription distribution model.
- Cann Group Limited: Australian medicinal cannabis cultivator and manufacturer supplying TGA-regulated cannabis medicines through similar prescription channels. Direct competitor to Bod in the Australian medicinal cannabis wholesale market with overlapping product formats.
- Little Green Pharma: Australian medicinal cannabis manufacturer producing pharmaceutical-grade cannabis oils supplied via SAS and Authorised Prescriber pathways. Direct competitor to Bod MediCabilis with comparable product formats and clinical positioning.
- MGC Pharmaceuticals: Australia- and UK-based medicinal cannabis company with phytomedicine products sold through prescription and pharmacy channels. Direct competitor in both of Bod's core operating geographies with similar TGA/SAS positioning.
- AusCann Group Holdings: Australian pharmaceutical-grade medicinal cannabis company producing cannabinoid-based medicines for chronic conditions. Comparable in regulatory pathway, product positioning, and patient-targeting model to Bod Science.
Others
- Lambert Initiative for Cannabinoid Research (University of Sydney): Bod's R&D partner and Australia's leading academic center for medicinal cannabis research. While not a commercial competitor, it is highly relevant given its co-development role with Bod's ECS315 and broader pipeline, and as a source of competing clinical evidence.
Broad incumbents
- Jazz Pharmaceuticals (GW Pharmaceuticals): Global specialty pharma company that acquired GW Pharmaceuticals, the originator of cannabinoid-based prescription medicines (Sativex, Epidiolex). Represents the gold standard for clinical-grade cannabis therapeutics and a long-term benchmark for Bod's clinical pipeline.
- Tilray Brands: Large global cannabis company with a pharmaceutical-grade medicinal cannabis portfolio including products in Australian and European markets. Significant competitive pressure on Bod due to scale, capital, and broader product range.
Emerging players
- Medlab Clinical: Australian biotech developing cannabinoid-based medicines with clinical research focus. Comparable to Bod in therapeutic positioning, clinical evidence emphasis, and Australian TGA pathway approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Bod Science social profiles
Digital presenceBod Science financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bod Science leadership team
Management profileNumber of profiles
Bod Science funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bod Science M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bod Science
What does Bod Science do?
Bod Science supplies pharmaceutical-grade medicinal cannabis products — primarily Bod MediCabilis (5% CBD full-spectrum oil using LINNEA 315CSE™) — as prescription-only medicines through Australia's TGA Special Access Scheme (SAS) and Authorised Prescriber pathways. The company maintains a clinical R&D pipeline of CBD, CBG, and CBN formulations (Bod Bio Absorb, Bod ECS315, Bod ECS317, Bod ECS100, Bod Es310) targeting insomnia, Motor Neuron Disease, Long Covid, anxiety, and inflammation, alongside proprietary wafer-based cannabinoid delivery technology.
Is Bod Science a public or private company?
Bod Science is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Bod Science founded?
Bod Science was founded in 2016. It employs 1 to 10 people.
Where is Bod Science based?
Bod Science is headquartered in Sydney, Australia, in the Oceania region.
How does Bod Science make money?
Two revenue lines are on record. Prescription Medicinal Cannabis Products are the primary driver. The others are clinical Trial Services.
Who are Bod Science's main competitors?
Direct peers on record are Althea Group Holdings, Zelira Therapeutics, Cann Group Limited, Little Green Pharma, MGC Pharmaceuticals and AusCann Group Holdings. Lambert Initiative for Cannabinoid Research (University of Sydney) is listed as an others. Broad incumbents are Jazz Pharmaceuticals (GW Pharmaceuticals) and Tilray Brands. Medlab Clinical is listed as an emerging player.
Does Bod Science have an API?
No public API is recorded for Bod Science.
What industry is Bod Science in?
Bod Science's product category is Medicinal Cannabis Pharmaceuticals. Its primary akta.pro industry code is CRANAHAC, CBD/Hemp Wellness & Supplements Retail, with a secondary code of CRANAFAB, Medical Cannabis Dispensaries. Its NAICS code is 325411 and its SIC code is 2833.